Sullivan Scores For New Client Teva In $40.5B Allergan Deal
If Monday's $40.5 billion deal between Teva Pharmaceutical Industries Ltd. and Allergan PLC is a big conquest for Teva, it's also a major coup for the Israeli generic-drug maker's acquisition counsel...To view the full article, register now.
Already a subscriber? Click here to view full article